Long-term survivor (LTS) characteristics in HER2+ metastatic breast cancer (MBC)

• Published in: Journal of clinical oncology Vol. 30; no. 27_suppl; p. 133
• Main Authors: Yardley, Denise Aysel, Tripathy, Debu, Brufsky, Adam M., Rugo, Hope S., Kaufman, Peter Andrew, Mayer, Musa, Feng, Shibao, Abidoye, Oyewale O., Ulcickas Yood, Marianne
• Format: Journal Article
• Language: English
• Published: 20.09.2012
• ISSN: 0732-183X; 1527-7755
• DOI: 10.1200/jco.2012.30.27_suppl.133

Abstract only 133 Background: Data characterizing LTS with HER2+ MBC are limited. The objective of this analysis is to describe LTS in terms of demographics, disease characteristics, and treatment history. Methods: registHER is an observational cohort of patients (pts) (N=1,001) with HER2+ MBC diagnosed w/in 6 mos of enrollment and followed until death, disenrollment, or 6/09 (median follow-up 27 mos). LTS were defined as pts who survived ≥36 mos from metastatic diagnosis (dx) (n=404). Baseline characteristics were examined. Multivariate analyses assessed factors associated with overall survival (OS) in all registHER pts. Results: Median progression-free survival in LTS was 17.9 mos (95% confidence interval (CI) 15.5-20.2). Similar to all registHER pts, median age at enrollment for LTS was 52 y (range 22,82), the majority were white (85.4%), and initial dx in over half of pts was stage I-III, MBC >12 mos (57.4%). LTS, however, were more likely to have estrogen receptor (ER)+ or progesterone receptor (PR)+ disease (61.6% and 52.9%, respectively) and a lower rate of underlying cardiovascular disease (CVD) (12.4% and 17.2%, respectively). First-line taxane and first-line trastuzumab use was higher in LTS pts. Physician-assessed first-line complete response was 40% in LTS and 22.8% in all registHER pts. Factors associated with OS in all registHER pts are shown in the table. Conclusions: This descriptive study examines factors commonly associated with long-term survival in pts with HER2+ MBC. LTS were primarily white, with ER+ or PR+ disease, and low rates of underlying CVD. Further study is needed to quantify the contribution of these factors to prolonging survival. [Table: see text]